AstraZeneca Signs an Agreement with Cobra Biologics for Vaccines Against COVID-19

 AstraZeneca Signs an Agreement with Cobra Biologics for Vaccines Against COVID-19

AstraZeneca Signs an Agreement with Cobra Biologics for Vaccines Against COVID-19

Shots:

  • AstraZeneca has signed a supply agreement with Cobra to provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19
  • The companies collaborated to provide large scale manufacturing capacity of the AZD1222 vaccine. Cobra will be manufacturing the vaccine with first deliveries to be initiated in the UK in Sep’2020
  • The agreement is part of AstraZeneca’s in-licensed program with the University of Oxford to ensure equitable supply of the vaccine across the globe, at no profit during the COVID-19 pandemic. The Cobra is a part of a consortium with the Jenner Institute, University of Oxford, and others, to ramp up the production of ChAdOx1 nCoV-19

Click here to read full press release/ article | Ref: AstraZeneca | Image: Twitter

Related News: AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post